The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant.
Justenhoven C, Obazee O, Winter S, Couch FJ, Olson JE, Hall P, Hannelius U, Li J, Humphreys K, Severi G, Giles G, Southey M, Baglietto L, Fasching PA, Beckmann MW, Ekici AB, Hamann U, Baisch C, Harth V, Rabstein S, Lotz A, Pesch B, Brüning T, Ko YD, Brauch H.
Justenhoven C, et al. Among authors: harth v.
Breast Cancer Res Treat. 2012 Jan;131(1):347-50. doi: 10.1007/s10549-011-1827-1. Epub 2011 Oct 26.
Breast Cancer Res Treat. 2012.
PMID: 22037784
No abstract available.